The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Current Progress in CAR-T Cell Therapy for Solid Tumors
Open accessAbstract
Cancer immunotherapy by chimeric antigen receptor-modified T (CAR-T) cells has shown exhilarative clinical efficacy for hematological malignancies. Recently two CAR-T cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) approved by US FDA (US Food and Drug Administration) are now used for treatment of B cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) respectively in the US. Despite the progresses made in treating hematological malignancies, challenges still remain for use of CAR-T cell therapy to treat solid tumors. In this landscape, most studies have primarily focused on improving CAR-T cells and overcoming the unfavorable effects of tumor microenvironment on solid tumors. To further understand the current status and trend for developing CAR-T cell based therapies for various solid tumors, this review emphasizes on CAR-T techniques, current obstacles, and strategies for application, as well as necessary companion diagnostics for treatment of solid tumors with CAR-T cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
Grupp, S. A., Kalos, M., Barrett, D., Aplenc, R., Porter, D. L., Rheingold, S. R., Teachey, D. T., Chew, A., Hauck, B., Wright, J. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1215134 · Cited by 3,509
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
CD28/B7 SYSTEM OF T CELL COSTIMULATION
Lenschow, D. J., Walunas, T. L., & Bluestone, J. A. (1996) · Annual Review of Immunology · doi:10.1146/annurev.immunol.14.1.233 · Cited by 2,717
Morgan, R. A., Yang, J. C., Kitano, M., Dudley, M. E., Laurencot, C. M., & Rosenberg, S. A. (2010) · Molecular Therapy · doi:10.1038/mt.2010.24 · Cited by 2,533
Chimeric antigen receptor T-cell therapy—assessment and management of toxicities
Neelapu, S. S., Tummala, S., Kebriaei, P., Wierda, W., Gutierrez, C., Locke, F. L., Komanduri, K. V., Lin, Y., Jain, N., Daver, N., et al. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.148 · Cited by 2,438
Feig, C., Jones, J. O., Kraman, M., Wells, R. J. B., Deonarine, A., Chan, D. S., Connell, C. M., Roberts, E. W., Zhao, Q., Caballero, O. L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320318110 · Cited by 2,100
Bretscher, P., & Cohn, M. (1970) · Science · doi:10.1126/science.169.3950.1042 · Cited by 1,692
Eshhar, Z., Waks, T., Gross, G., & Schindler, D. G. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.2.720 · Cited by 1,658
Harding, F. A., McArthur, J. G., Gross, J. A., Raulet, D. H., & Allison, J. P. (1992) · Nature · doi:10.1038/356607a0 · Cited by 1,559
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
Di Stasi, A., Tey, S.-K., Dotti, G., Fujita, Y., Kennedy-Nasser, A., Martinez, C., Straathof, K., Liu, E., Durett, A. G., Grilley, B., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106152 · Cited by 1,512
The patterns and dynamics of genomic instability in metastatic pancreatic cancer
Campbell, P. J., Yachida, S., Mudie, L. J., Stephens, P. J., Pleasance, E. D., Stebbings, L. A., Morsberger, L. A., Latimer, C., McLaren, S., Lin, M.-L., et al. (2010) · Nature · doi:10.1038/nature09460 · Cited by 1,317
A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian Cancer
Kershaw, M. H., Westwood, J. A., Parker, L. L., Wang, G., Eshhar, Z., Mavroukakis, S. A., White, D. E., Wunderlich, J. R., Canevari, S., Rogers-Freezer, L., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1183 · Cited by 1,254
Milone, M. C., Fish, J. D., Carpenito, C., Carroll, R. G., Binder, G. K., Teachey, D., Samanta, M., Lakhal, M., Gloss, B., Danet-Desnoyers, G., et al. (2009) · Molecular Therapy · doi:10.1038/mt.2009.83 · Cited by 1,197
Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition
Cherkassky, L., Morello, A., Villena-Vargas, J., Feng, Y., Dimitrov, D. S., Jones, D. R., Sadelain, M., & Adusumilli, P. S. (2016) · Journal of Clinical Investigation · doi:10.1172/jci83092 · Cited by 1,074
Savoldo, B., Ramos, C. A., Liu, E., Mims, M. P., Keating, M. J., Carrum, G., Kamble, R. T., Bollard, C. M., Gee, A. P., Mei, Z., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci46110 · Cited by 1,023
Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aaf8621 · Cited by 1,016 · cited 1×
“Toxicity can also be minimized by controlling CAR-T cell activity through manipulating CAR expression and introducing a switch that can be triggered in the severe condition of the irAE [52, 53].”
BackgroundLamers, C. H. J., Sleijfer, S., Vulto, A. G., Kruit, W. H. J., Kliffen, M., Debets, R., Gratama, J. W., Stoter, G., & Oosterwijk, E. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.9964 · Cited by 915
Kloss, C. C., Condomines, M., Cartellieri, M., Bachmann, M., & Sadelain, M. (2013) · Nature Biotechnology · doi:10.1038/nbt.2459 · Cited by 857
Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes
Caruana, I., Savoldo, B., Hoyos, V., Weber, G., Liu, H., Kim, E. S., Ittmann, M. M., Marchetti, D., & Dotti, G. (2015) · Nature Medicine · doi:10.1038/nm.3833 · Cited by 814
Adachi, K., Kano, Y., Nagai, T., Okuyama, N., Sakoda, Y., & Tamada, K. (2018) · Nature Biotechnology · doi:10.1038/nbt.4086 · Cited by 792
Rupp, L. J., Schumann, K., Roybal, K. T., Gate, R. E., Ye, C. J., Lim, W. A., & Marson, A. (2017) · Scientific Reports · doi:10.1038/s41598-017-00462-8 · Cited by 757
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
Maude, S. L., Barrett, D., Teachey, D. T., & Grupp, S. A. (2014) · The Cancer Journal · doi:10.1097/ppo.0000000000000035 · Cited by 752
Fedorov, V. D., Themeli, M., & Sadelain, M. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006597 · Cited by 735
Till, B. G., Jensen, M. C., Wang, J., Chen, E. Y., Wood, B. L., Greisman, H. A., Qian, X., James, S. E., Raubitschek, A., Forman, S. J., et al. (2008) · Blood · doi:10.1182/blood-2007-12-128843 · Cited by 722
Obstacles Posed by the Tumor Microenvironment to T cell Activity: A Case for Synergistic Therapies
Anderson, K. G., Stromnes, I. M., & Greenberg, P. D. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.02.008 · Cited by 702
The two faces of IL-6 in the tumor microenvironment
Fisher, D. T., Appenheimer, M. M., & Evans, S. S. (2014) · Seminars in Immunology · doi:10.1016/j.smim.2014.01.008 · Cited by 693
Remote control of therapeutic T cells through a small molecule–gated chimeric receptor
Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015) · Science · doi:10.1126/science.aab4077 · Cited by 687
Stability engineering of antibody single-chain Fv fragments
Wörn, A., & Plückthun, A. (2001) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.4265 · Cited by 616
Circulating and disseminated tumour cells — mechanisms of immune surveillance and escape
Mohme, M., Riethdorf, S., & Pantel, K. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.144 · Cited by 602
Hoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 567
Chmielewski, M., Kopecky, C., Hombach, A. A., & Abken, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0103 · Cited by 562
Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression
Wang, G., Lu, X., Dey, P., Deng, P., Wu, C. C., Jiang, S., Fang, Z., Zhao, K., Konaparthi, R., Hua, S., et al. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0224 · Cited by 553
Zhong, X.-S., Matsushita, M., Plotkin, J., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2009.210 · Cited by 543
Targeting tumours with genetically enhanced T lymphocytes
Sadelain, M., Rivière, I., & Brentjens, R. (2003) · Nature Reviews Cancer · doi:10.1038/nrc971 · Cited by 535
Heczey, A., Louis, C. U., Savoldo, B., Dakhova, O., Durett, A., Grilley, B., Liu, H., Wu, M. F., Mei, Z., Gee, A., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.05.012 · Cited by 535
Di Stasi, A., De Angelis, B., Rooney, C. M., Zhang, L., Mahendravada, A., Foster, A. E., Heslop, H. E., Brenner, M. K., Dotti, G., & Savoldo, B. (2009) · Blood · doi:10.1182/blood-2009-03-209650 · Cited by 533
Craddock, J. A., Lu, A., Bear, A., Pule, M., Brenner, M. K., Rooney, C. M., & Foster, A. E. (2010) · Journal of Immunotherapy · doi:10.1097/cji.0b013e3181ee6675 · Cited by 513
Ciceri, F., Bonini, C., Stanghellini, M. T. L., Bondanza, A., Traversari, C., Salomoni, M., Turchetto, L., Colombi, S., Bernardi, M., Peccatori, J., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70074-9 · Cited by 488
Kowolik, C. M., Topp, M. S., Gonzalez, S., Pfeiffer, T., Olivares, S., Gonzalez, N., Smith, D. D., Forman, S. J., Jensen, M. C., & Cooper, L. J. N. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0160 · Cited by 487
TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
Grada, Z., Hegde, M., Byrd, T., Shaffer, D. R., Ghazi, A., Brawley, V. S., Corder, A., Schönfeld, K., Koch, J., Dotti, G., et al. (2013) · Molecular Therapy - Nucleic Acids · doi:10.1038/mtna.2013.32 · Cited by 458
Johnson, L. A., Scholler, J., Ohkuri, T., Kosaka, A., Patel, P. R., McGettigan, S. E., Nace, A. K., Dentchev, T., Thekkat, P., Loew, A., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa4963 · Cited by 454
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Koneru, M., Purdon, T. J., Spriggs, D., Koneru, S., & Brentjens, R. J. (2015) · OncoImmunology · doi:10.4161/2162402x.2014.994446 · Cited by 418
Trafficking of T Cells into Tumors
Slaney, C. Y., Kershaw, M. H., & Darcy, P. K. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-2458 · Cited by 410
Moon, E. K., Wang, L.-C., Dolfi, D. V., Wilson, C. B., Ranganathan, R., Sun, J., Kapoor, V., Scholler, J., Puré, E., Milone, M. C., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2627 · Cited by 404
Immunosuppressive cells in tumor immune escape and metastasis
Liu, Y., & Cao, X. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-015-1376-x · Cited by 400
Caruso, H. G., Hurton, L. V., Najjar, A., Rushworth, D., Ang, S., Olivares, S., Mi, T., Switzer, K., Singh, H., Huls, H., et al. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0139 · Cited by 397
A two-step, two-signal model for the primary activation of precursor helper T cells
Bretscher, P. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.185 · Cited by 386
Lesokhin, A. M., Hohl, T. M., Kitano, S., Cortez, C., Hirschhorn-Cymerman, D., Avogadri, F., Rizzuto, G. A., Lazarus, J. J., Pamer, E. G., Houghton, A. N., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1792 · Cited by 378
Brentjens, R., Yeh, R., Bernal, Y., Riviere, I., & Sadelain, M. (2010) · Molecular Therapy · doi:10.1038/mt.2010.31 · Cited by 377
Hegde, M., Corder, A., Chow, K. K., Mukherjee, M., Ashoori, A., Kew, Y., Zhang, Y. J., Baskin, D. S., Merchant, F. A., Brawley, V. S., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.185 · Cited by 373
Retargeting of Human T Cells to Tumor-Associated MUC1: The Evolution of a Chimeric Antigen Receptor
Wilkie, S., Picco, G., Foster, J., Davies, D. M., Julien, S., Cooper, L., Arif, S., Mather, S. J., Taylor-Papadimitriou, J., Burchell, J. M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.7.4901 · Cited by 346
Antitumor Effects of Chimeric Receptor Engineered Human T Cells Directed to Tumor Stroma
Kakarla, S., Chow, K. K., Mata, M., Shaffer, D. R., Song, X.-T., Wu, M.-F., Liu, H., Wang, L. L., Rowley, D. R., Pfizenmaier, K., et al. (2013) · Molecular Therapy · doi:10.1038/mt.2013.110 · Cited by 346
Suarez, E. R., Chang, D.-K., Sun, J., Sui, J., Freeman, G. J., Signoretti, S., Zhu, Q., & Marasco, W. A. (2016) · Oncotarget · doi:10.18632/oncotarget.9114 · Cited by 340
Lanitis, E., Poussin, M., Klattenhoff, A. W., Song, D., Sandaltzopoulos, R., June, C. H., & Powell, D. J. (2013) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0008 · Cited by 329
Priceman, S. J., Tilakawardane, D., Jeang, B., Aguilar, B., Murad, J. P., Park, A. K., Chang, W.-C., Ostberg, J. R., Neman, J., Jandial, R., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2041 · Cited by 327
Bollard, C. M., Rössig, C., Calonge, M. J., Huls, M. H., Wagner, H.-J., Massague, J., Brenner, M. K., Heslop, H. E., & Rooney, C. M. (2002) · Blood · doi:10.1182/blood.v99.9.3179 · Cited by 316
Morgan, R. A., Johnson, L. A., Davis, J. L., Zheng, Z., Woolard, K. D., Reap, E. A., Feldman, S. A., Chinnasamy, N., Kuan, C.-T., Song, H., et al. (2012) · Human Gene Therapy · doi:10.1089/hum.2012.041 · Cited by 311
Li, S., Siriwon, N., Zhang, X., Yang, S., Jin, T., He, F., Kim, Y. J., Mac, J., Lu, Z., Wang, S., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0867 · Cited by 300
Kershaw, M. H., Wang, G., Westwood, J. A., Pachynski, R. K., Tiffany, H. L., Marincola, F. M., Wang, E., Young, H. A., Murphy, P. M., & Hwu, P. (2002) · Human Gene Therapy · doi:10.1089/10430340260355374 · Cited by 297
Zhang, L., Kerkar, S. P., Yu, Z., Zheng, Z., Yang, S., Restifo, N. P., Rosenberg, S. A., & Morgan, R. A. (2011) · Molecular Therapy · doi:10.1038/mt.2010.313 · Cited by 293
Mohammed, S., Sukumaran, S., Bajgain, P., Watanabe, N., Heslop, H. E., Rooney, C. M., Brenner, M. K., Fisher, W. E., Leen, A. M., & Vera, J. F. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2016.10.016 · Cited by 281
Drent, E., Themeli, M., Poels, R., de Jong-Korlaar, R., Yuan, H., de Bruijn, J., Martens, A. C. M., Zweegman, S., van de Donk, N. W. C. J., Groen, R. W. J., et al. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.024 · Cited by 276
Richman, S. A., Nunez-Cruz, S., Moghimi, B., Li, L. Z., Gershenson, Z. T., Mourelatos, Z., Barrett, D. M., Grupp, S. A., & Milone, M. C. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0211 · Cited by 267
Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors
Harris, D. T., & Kranz, D. M. (2016) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.11.004 · Cited by 257
Kerkar, S. P., Muranski, P., Kaiser, A., Boni, A., Sanchez-Perez, L., Yu, Z., Palmer, D. C., Reger, R. N., Borman, Z. A., Zhang, L., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0735 · Cited by 254
Chinnasamy, D., Yu, Z., Theoret, M. R., Zhao, Y., Shrimali, R. K., Morgan, R. A., Feldman, S. A., Restifo, N. P., & Rosenberg, S. A. (2010) · Journal of Clinical Investigation · doi:10.1172/jci43490 · Cited by 253
Burga, R. A., Thorn, M., Point, G. R., Guha, P., Nguyen, C. T., Licata, L. A., DeMatteo, R. P., Ayala, A., Joseph Espat, N., Junghans, R. P., et al. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-015-1692-6 · Cited by 230
Manning, E. A., Ullman, J. G. M., Leatherman, J. M., Asquith, J. M., Hansen, T. R., Armstrong, T. D., Hicklin, D. J., Jaffee, E. M., & Emens, L. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0374 · Cited by 205
Loskog, A., Giandomenico, V, Rossig, C., Pule, M., Dotti, G., & Brenner, M. K. (2006) · Leukemia · doi:10.1038/sj.leu.2404366 · Cited by 192
Park, S., Shevlin, E., Vedvyas, Y., Zaman, M., Park, S., Hsu, Y.-M. S., Min, I. M., & Jin, M. M. (2017) · Scientific Reports · doi:10.1038/s41598-017-14749-3 · Cited by 163
Arcangeli, S., Rotiroti, M. C., Bardelli, M., Simonelli, L., Magnani, C. F., Biondi, A., Biagi, E., Tettamanti, S., & Varani, L. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.04.017 · Cited by 152
Gross, G., & Eshhar, Z. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010814-124844 · Cited by 149
PSCA and MUC1 in non-small-cell lung cancer as targets of chimeric antigen receptor T cells
Wei, X., Lai, Y., Li, J., Qin, L., Xu, Y., Zhao, R., Li, B., Lin, S., Wang, S., Wu, Q., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1284722 · Cited by 147
Circulating Tumor Cells: Moving Biological Insights into Detection
Chen, L., Bode, A. M., & Dong, Z. (2017) · Theranostics · doi:10.7150/thno.18588 · Cited by 145
Chimeric-antigen receptor T (CAR-T) cell therapy for solid tumors: challenges and opportunities
Xia, A., Wang, X., Lu, Y., Lu, X., & Sun, B. (2017) · Oncotarget · doi:10.18632/oncotarget.19361 · Cited by 140
Self-citationHaynes, N. M., Snook, M. B., Trapani, J. A., et al. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.182 · Cited by 139
EGFRvIII‐Targeted Vaccination Therapy of Malignant Glioma
Choi, B. D., Archer, G. E., Mitchell, D. A., Heimberger, A. B., McLendon, R. E., Bigner, D. D., & Sampson, J. H. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00318.x · Cited by 139
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
John, L. B., Kershaw, M. H., & Darcy, P. K. (2013) · OncoImmunology · doi:10.4161/onci.26286 · Cited by 134
CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy
Chen, N., Morello, A., Tano, Z. E., & Adusumilli, P. S. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1273302 · Cited by 134
Engineering Aggregation-Resistant Antibodies
Perchiacca, J. M., & Tessier, P. M. (2012) · Annual Review of Chemical and Biomolecular Engineering · doi:10.1146/annurev-chembioeng-062011-081052 · Cited by 128
Marin, V., Cribioli, E., Philip, B., Tettamanti, S., Pizzitola, I., Biondi, A., Biagi, E., & Pulè, M. A. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.050 · Cited by 127
van Schalkwyk, M. C., Papa, S., Jeannon, J., Urbano, T. G., Spicer, J. F., & Maher, J. F. (2013) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2013.144 · Cited by 126
Oren, R., Hod-Marco, M., Haus‐Cohen, M., Thomas, S., Blat, D., Duvshani, N., Denkberg, G., Elbaz‐Alon, Y., Benchetrit, F., Eshhar, Z., et al. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301769 · Cited by 124
High-affinity FRβ-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity
Lynn, R. C., Feng, Y., Schutsky, K., Poussin, M., Kalota, A., Dimitrov, D. S., & Powell, D. J., Jr. (2016) · Leukemia · doi:10.1038/leu.2016.35 · Cited by 122
Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors
Zhang, B., Qin, D., Mo, Z., Li, Y., Wei, W., Wang, Y., Wang, W., & Wei, Y.-Q. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5027-4 · Cited by 116
Künkele, A., Taraseviciute, A., Finn, L. S., Johnson, A., Berger, C., Finney, O. C., Chang, C. A., Rolczynski, L. S., Brown, C., Mgebroff, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0354 · Cited by 114
Lee, J., Hayman, E. G., Pegram, H. J., Santos, E. B., Heller, G., Sadelain, M., & Brentjens, R. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-0552 · Cited by 102
New Strategies for the Treatment of Solid Tumors with CAR-T Cells
Zhang, H., Ye, Z., Yuan, Z.-G., Luo, Z.-Q., Jin, H., & Qian, Q. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.14405 · Cited by 101
Self-citationKoehler, H., Kofler, D. M., Hombach, A. A., & Abken, H. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2098 · Cited by 95
Song, D.-G., Ye, Q., Poussin, M., Liu, L., Figini, M., & Powell, D. J. (2015) · Oncotarget · doi:10.18632/oncotarget.4071 · Cited by 94
Wang, W., Ma, Y., Li, J., Shi, H., Lq, W., Guo, F.-C., Zhang, J., Li, D., Mo, B.-H., Wen, F., et al. (2013) · Gene Therapy · doi:10.1038/gt.2013.19 · Cited by 93
Abate‐Daga, D., Hanada, K., Davis, J. L., Yang, J. C.-H., Rosenberg, S. A., & Morgan, R. A. (2013) · Blood · doi:10.1182/blood-2013-04-495531 · Cited by 93
Driving cars to the clinic for solid tumors
Castellarin, M. L., Watanabe, K., June, C. H., Kloss, C. C., & Posey, A. D. (2018) · Gene Therapy · doi:10.1038/s41434-018-0007-x · Cited by 93
Wallace, A. F., Kapoor, V., Sun, J., Mrass, P., Weninger, W., Heitjan, D. F., June, C. H., Kaiser, L. R., Ling, L. E., & Albelda, S. Μ. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0356 · Cited by 87
Beatty, G. L., & Moon, E. K. (2014) · OncoImmunology · doi:10.4161/21624011.2014.970027 · Cited by 85
Nishio, N., & Dotti, G. (2015) · OncoImmunology · doi:10.4161/21505594.2014.988098 · Cited by 83
Trial Watch: Adoptively transferred cells for anticancer immunotherapy
Fournier, C., Martin, F., Zitvogel, L., Kroemer, G., Galluzzi, L., & Apétoh, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1363139 · Cited by 82
EGF receptor variant III as a target antigen for tumor immunotherapy
Li, G., & Wong, A. J. (2008) · Expert Review of Vaccines · doi:10.1586/14760584.7.7.977 · Cited by 74
Adnectin-Based Design of Chimeric Antigen Receptor for T Cell Engineering
Han, X., Cinay, G. E., Zhao, Y., Guo, Y., Zhang, X., & Wang, P. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.07.009 · Cited by 66
Heuser-Loy, C., Hombach, A. A., Lösch, C., Manista, K., & Abken, H. (2003) · Gene Therapy · doi:10.1038/sj.gt.3302023 · Cited by 55
Altvater, B., Landmeier, S., Pscherer, S., Temme, J., Juergens, H., Pulè, M. A., & Rössig, C. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-009-0704-9 · Cited by 47
Seatbelts in CAR therapy: How Safe Are CARS?
Minagawa, K., Zhou, X., Mineishi, S., & Stasi, A. D. (2015) · Pharmaceuticals · doi:10.3390/ph8020230 · Cited by 43
Hegde, U. P., & Mukherji, B. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-2007-x · Cited by 35
Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors
Han, S., Latchoumanin, O., Wu, G. J., Zhou, G., Hebbard, L., George, J., & Qiao, L. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.12.037 · Cited by 34
Schmidt, K., Zilio, S., Schmollinger, J. C., Bronte, V., Blankenstein, T. J. F., & Willimsky, G. (2013) · Blood · doi:10.1182/blood-2012-06-436568 · Cited by 32
Zhang, Q., Wang, H., Li, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.14367 · Cited by 24
Belický, Š., Damborský, P., Zapatero-Rodríguez, J., et al. (2017) · Electrochimica Acta · doi:10.1016/j.electacta.2017.06.065 · Cited by 19
Targeting the tumour profile using broad spectrum chimaeric antigen receptor T-cells
Navai, S. A., & Ahmed, N. M. (2016) · Biochemical Society Transactions · doi:10.1042/bst20150266 · Cited by 16
Spotlight on chimeric antigen receptor engineered T cell research and clinical trials in China
Luo, C., Wei, J., & Han, W. (2016) · Science China Life Sciences · doi:10.1007/s11427-016-5034-5 · Cited by 13
Tumor-Targeting Domains for Chimeric Antigen Receptor T Cells
Bezverbnaya, K., Mathews, A., Sidhu, J., Helsen, C. W., & Bramson, J. L. (2016) · Immunotherapy · doi:10.2217/imt-2016-0103 · Cited by 10
Cited by
Colorectal Cancer Immunotherapy: Options and Strategies
Johdi, N. A., & Sukor, N. F. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01624 · Cited by 452
CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors
Peng, L., Sferruzza, G., Yang, L., Zhou, L., & Chen, S. (2024) · Cellular & Molecular Immunology · doi:10.1038/s41423-024-01207-0 · Cited by 373
Cancer Therapy With TCR-Engineered T Cells: Current Strategies, Challenges, and Prospects
Shafer, P., Kelly, L. M., & Hoyos, V. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.835762 · Cited by 270
Hypoxia and the phenomenon of immune exclusion
Pietrobon, V., & Marincola, F. M. (2021) · Journal of Translational Medicine · doi:10.1186/s12967-020-02667-4 · Cited by 119
Targeting CLDN18.2 in cancers of the gastrointestinal tract: new drugs and new indications
Chen, J., Xu, Z., Hu, C., Zhang, S., Zi, M., Yuan, L., & Cheng, X. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1132319 · Cited by 78
Metadata
- Authors
- Ma, S., Li, X., Wang, X., Cheng, L., Li, Z., Zhang, C., Ye, Z., & Qian, Q.
- Venue
- International Journal of Biological Sciences
- Publisher
- Ivyspring International Publisher
- Published
- 2019
- Volume
- 15
- Issue
- 12
- Pages
- 2548-2560
- ISSN
- 1449-2288 (ISSN-L)
- OpenAlex
- W2976192812
- Cited by
- 496
- References
- 113
- FWCI
- 15.05
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.